乌帕替尼

乌帕替尼（CAS 1310726-60-3）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Upadacitinib is a new FDA-approved second-line agent for treating moderate to severe active rheumatoid arthritis (RA) in patients who have not shown an adequate response or intolerance to the first-line agent, methotrexate. This agent is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme. Upadacitinib received FDA approval on August 16, 2019, based on positive and promising results from its multinational phase III trials in subjects with moderate to severe rheumatoid arthritis.Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis. Upadacitinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.

同义词与商品名

Upadacitinib; 1310726-60-3; ABT-494; Upadacitinib anhydrous; 4RA0KN46E0; DTXSID901027919; upadacitinibum; RefChem:57163; L04AA44; DTXCID401513480; Rinvoq; ABT 494; EX-A1628; DB15091; ABBV-599 COMPONENT UPADACITINIB; UNII-4RA0KN46E0

公开数据库对它的描述

Upadacitinib · CAS 1310726-60-3 · C17H19F3N6O. UNII 4RA0KN46E0. Boiling Point: 189; Melting Point: 16-19.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。